• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

RCT Results: 200 mg vs 1000 mg DHA for Reduction of Early Preterm Birth?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • n-3 fatty acids, such as docosahexaenoic acid (DHA), have been shown in meta-analyses to reduce the risk of early preterm birth
    • However, the required dose of DHA is unclear
  • Carlson et al. (EClinicalMedicine, 2021) conducted a superiority trial comparing the standard 200 mg DHA dose, often found in prenatal supplements, vs 1000 mg

METHODS:

  • Randomized, multicenter, double-blind, adaptive-design, superiority trial
    • NICHD funded
  • Participants
    • Singleton pregnancies
    • 12 to 20 weeks gestation
  • Intervention
    • 1000 mg DHA
    • 200 mg DHA (standard)
  • Study design
    • Women were randomized by participating site in blocks of 4
    • Adaptive design: Allocation ratios that favor the better performing dose are periodically generated with the goal of saving time, study resources and may be more ethical
      • Simulations performed to determine design that optimizes time and number of patients required
    • Bayesian posterior probabilities (pp) were determined for planned efficacy and safety outcomes using intention-to-treat
    • In addition to dichotomous design, a continuous time-to-event value was also calculated
  • Primary outcome
    • Early preterm birth

RESULTS:

  • 1000 mg dose: 540 participants | 200 mg dose: 492 participants
  • The higher DHA dose was associated with a lower rate of early preterm birth
    • 1000 mg: 1.7%
    • 200 mg: 2.4%
    • pp = 0.81
  • Using continuous time-to-event value and Baysian credible intervals (CI)  
    • 1000 mg: 1.7% (95% CI, 0.8% to 2.8%)
    • 200 mg: 2.9% (95% CI, 1.6% to 4.3%)
    • pp=0.91

Note: “A pp = 0.81 or 0.91 is much larger than an indifferent probability of 0.50 but not as strong as almost certainty (e.g., > 0.99)”

  • This association was especially strong if participants had a low DHA status at enrollment
    • 1000mg w/ low DHA at enrollment: 2.0%
    • 200 mg w/ low DHA at enrollment: 4.1%
    • pp = 0.93
  • Participants who had high DHA levels at enrollment did not see a difference in early preterm birth rates with the different DHA doses
    • 1000 mg w/ high DHA at enrollment: 1.4%
    • 200 mg w/ high DHA at enrollment: 1.1%
    • pp = 0.57
  • The higher dose of DHA was also associated with fewer serious adverse events such as (all pp>0.90)
    • Chorioamnionitis
    • Premature rupture of membranes and pyelonephritis
    • Feeding problems
    • Genitourinary and neurologic problems

CONCLUSION:

  • For women with low levels of DHA, supplementing with 1000 mg of DHA confers a greater benefit for reducing early preterm birth risk vs 200 mg
  • When women are able to be screened for DHA, clinicians should consider prescribing a 1000 mg dose of DHA to women with low levels
  • The authors suggest the following regarding policy

Regarding policy, the National Academy of Medicine in the USA could now set a Dietary Recommended Intake for DHA in pregnancy, not possible before an amount of DHA could be linked to lower EPB

Regarding clinical practice, clinicians could consider testing DHA status and offering high dose DHA supplementation to those with low DHA status

Women with high DHA status at enrolment should be encouraged to take a prenatal with 200 mg DHA 

Learn More – Primary Sources:

Higher dose docosahexaenoic acid supplementation during pregnancy and early preterm birth: A randomised, double-blind, adaptive-design superiority trial

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Does DHA Improve Cognition in Children?
Does N-3 Long-Chain Polyunsaturated Fatty Acid Supplementation Decrease Early Preterm Births?
Cochrane Review: Do Omega-3 Fatty Acids Reduce Cardiovascular Disease? 

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site